In CRC, MCL-1 inhibitors can be used to overcome mutant FBXW7-driven regorafenib resistance and contribute to the development of precision therapies to improve CRC treatment (Song et al., 2020). The gene discussed is MCL1; the disease is colorectal carcinoma.